Smith Chas P & Associates PA Cpas raised its position in Johnson & Johnson (NYSE:JNJ) by 2.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 150,817 shares of the company’s stock after buying an additional 3,356 shares during the period. Johnson & Johnson comprises about 3.1% of Smith Chas P & Associates PA Cpas’ holdings, making the stock its 11th largest position. Smith Chas P & Associates PA Cpas’ holdings in Johnson & Johnson were worth $18,294,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of the company. Americafirst Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $101,000. INR Advisory Services LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $150,000. Capital Asset Advisory Services LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $202,000. Inspirion Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $210,000. Finally, NewSquare Capital LLC increased its stake in shares of Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock worth $217,000 after buying an additional 83 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) traded down 0.59% during mid-day trading on Friday, hitting $117.56. The company had a trading volume of 5,640,519 shares. The firm’s 50 day moving average is $118.72 and its 200 day moving average is $117.37. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07. The company has a market capitalization of $321.63 billion, a price-to-earnings ratio of 21.91 and a beta of 0.62.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion. On average, equities research analysts predict that Johnson & Johnson will post $6.69 EPS for the current year.
A number of brokerages have commented on JNJ. Credit Suisse Group AG reissued a “neutral” rating and issued a $123.00 price objective on shares of Johnson & Johnson in a research note on Monday, September 19th. Wells Fargo & Co. reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 11th. BMO Capital Markets reissued an “outperform” rating and issued a $132.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective for the company in a research note on Friday, August 5th. Finally, Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $123.13 price objective for the company in a research note on Tuesday, September 27th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $120.20.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares in the company, valued at $3,582,786.60. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.